Last update 29 Jun 2026

NS-863

Overview

Basic Info

Drug Type
Biological products
Synonyms
NS 863, NS863
Target-
Action-
Mechanism-
Therapeutic Areas
Respiratory DiseasesOther DiseasesCardiovascular Diseases
Active Indication
Familial Primary Pulmonary HypertensionIdiopathic pulmonary arterial hypertensionPulmonary arterial hypertension associated with congenital heart disease+ [2]
Inactive Indication-
Originator Organization
Nippon Shinyaku Co., Ltd.Nippon Shinyaku Co., Ltd.
Active Organization
NS Pharma, Inc.NS Pharma, Inc.Nippon Shinyaku Co., Ltd.Nippon Shinyaku Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with NS-863
NCT07441200
/ Not yet recruitingPhase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441278
/ Not yet recruitingPhase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
JPRN-jRCT2031260138
/ Not yet recruitingPhase 1
Pharmacokinetic study of NS-863 in subjects with renal impairment (Phase I Study)
100 Clinical Results associated with NS-863
Login to view more data
100 Translational Medicine associated with NS-863
Login to view more data
100 Patents (Medical) associated with NS-863
Login to view more data
100 Deals associated with NS-863
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Familial Primary Pulmonary HypertensionPhase 2-
NS Pharma, Inc.NS Pharma, Inc.
01 Jul 2026
Idiopathic pulmonary arterial hypertensionPhase 2-
NS Pharma, Inc.NS Pharma, Inc.
01 Jul 2026
Pulmonary arterial hypertension associated with congenital heart diseasePhase 2-
NS Pharma, Inc.NS Pharma, Inc.
01 Jul 2026
Pulmonary hypertension due to interstitial lung diseasePhase 2-
NS Pharma, Inc.NS Pharma, Inc.
01 Jul 2026
Cardiovascular DiseasesPhase 1-
Nippon Shinyaku Co., Ltd.Nippon Shinyaku Co., Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free